Navigation Links
ESAs and a New Class of Late Stage Oral HIF-PH Inhibitors May Be Impacted by the Fact That Nephrologists Report Initiating ESAs at Lower Hemoglobins

EXTON, Pa., April 4, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to just one year ago, the mean hemoglobin at erythropoiesis-stimulating agent (ESA) initiation has significantly declined and is nearing levels at which a blood transfusion may be required. In addition, nephrologists tend to overestimate the percent of stage 3 chronic kidney disease (CKD) patients on an ESA, but accurately assess the percent of patients being treated with an ESA in stage 4 and stage 5 non-dialysis. Amgen's Aranesp has a slightly higher share of late-stage CKD patients than do the other available ESAs, including Procrit (manufactured by Amgen and distributed by Janssen) and Amgen's Epogen.

(Logo: )

The ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) report also covers the use of oral iron and IV iron in CKD-ND patients. AMAG Pharmaceutical's Feraheme, in number two share position behind Venofer, recently announced FDA acceptance of supplemental new drug application for label expansion to include iron deficiency anemia patients who cannot take oral iron. In addition, this study found that Feraheme patient share has declined directionally from 2011 with directional increases of the use of Sanofi's Ferrlecit."In this study, nearly half of physicians report initiating ESAs in CKD-ND at lower hemoglobin levels in the past year, something evident in the patient audit portion of this study as well," said BioTrends Research Group Director of Nephrology Rob Dubman . "This report could also have implications for the late-stage oral HIF-PH inhibitors in development, for example Akebia Therapeutics' AKB-6548 or FibroGen's/Astellas's FG-4592/ASP1517."

The BioTrends' TreatmentTrends: Nephrology (US) Q4 2012 report, found that over 20 percent of nephrologists expect to use AKB-6548 and FG-4592/ASP1517 products after ESA failures, respectively. Late stage oral HIF-PH inhibitors manufacturers must be considering when and how these agents will be used, especially when physicians are waiting longer to initiate ESAs.ChartTrends®: Renal Anemia in CKD-ND 2012 (U.S.) is a syndicated report series, in which 226 U.S. nephrologists provide patient chart data on 1,130 CKD-ND patients in the U.S. to uncover the actual management related to renal anemia. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers.

TreatmentTrends®: Nephrology (U.S.) is a syndicated quarterly report series, based on primary market research that provides a comprehensive view of the current and expected future management of renal anemia and bone and mineral metabolism in patients with kidney disease. The Q1 2013 wave published in March 2013 and the Q2 2013 wave will publish in June with survey comments due April 10, 2013.

About BioTrends Research GroupBioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research GroupDecision Resources GroupRob Dubman

Christopher Comfort781-993-2592


SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
2. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
3. Medifast, Inc. Announces Favorable Resolution of Securities Class Action Lawsuit
4. Star Scientific Responds to Plaintiffs Purported Class Action Lawsuit
5. Class III Obese Patients Experience Adverse Events More Frequently Than the General Adverse Event Patient Population
6. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
7. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
8. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
9. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
10. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):